In particular, immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 have significantly improved clinical outcomes in patients with melanoma, non-small cell lung cancer, and renal cell carcinoma [31–33]. This evidence concerns the gene CTLA4 and melanoma.